M. Burger

发表

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas

K. Franz, J. Steinbach, P. Harter, 2017, International journal of molecular sciences.

Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma

J. Steinbach, M. Mittelbronn, P. Harter, 2018, Journal of neurochemistry.

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

G. Tabatabai, H. Clusmann, H. Vatter, 2022, Trials.

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors

J. Steinbach, C. Senft, M. Mittelbronn, 2015, PloS one.

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern

J. Steinbach, M. Mittelbronn, O. Bähr, 2017, International journal of molecular sciences.

Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis

S. Fröhling, E. Hattingen, K. Franz, 2022, Journal of Neuro-Oncology.

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

W. Wels, J. Steinbach, T. Tonn, 2019, Front. Immunol..

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.

E. Hattingen, W. Wels, J. Steinbach, 2016, Journal of the National Cancer Institute.

PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma.

M. Weller, M. Eccles, T. Klingebiel, 2012, International journal of oncology.

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

W. Wels, J. Steinbach, Sabrina Genssler, 2016, Oncoimmunology.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

M. Weller, D. Cahill, K. Plate, 2018, Nature Medicine.

Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas

Anne K. Braczynski, K. Plate, S. Fulda, 2016, Oncotarget.

Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic–Induced Apoptosis

S. Fulda, S. Hehlgans, F. Rödel, 2016, Molecular Cancer Therapeutics.

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

D. Schiff, W. Wick, G. Tabatabai, 2021, Clinical Cancer Research.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

M. Weller, D. Cahill, K. Plate, 2018, Nature Medicine.

Disruption of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells

U. Hofmann, J. Steinbach, P. Harter, 2018, The Journal of Biological Chemistry.

Local Anesthetic-Induced Central Nervous System Toxicity during Interscalene Brachial Plexus Block: A Case Series Study of Three Patients

K. Jahnke, C. Kell, Daniel Spitzer, 2021, Journal of clinical medicine.

Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas

K. Franz, E. Fokas, J. Steinbach, 2021, Oncology.

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

K. Franz, E. Fokas, J. Steinbach, 2017, Oncology Letters.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

G. Stoffels, K. Langen, D. Capper, 2017, Oncology reports.

Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide

D. Kögel, C. Münch, B. Linder, 2021, Cancers.

Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032

H. Schwalbe, E. Hattingen, C. Richter, 2020, Cancers.

Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases

K. Franz, J. Steinbach, C. Senft, 2018, Journal of clinical medicine.

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors

K. Jahnke, J. Steinbach, M. Mittelbronn, 2016, PloS one.

AMPK activation protects astrocytes from hypoxia-induced cell death

J. Steinbach, M. Voss, M. Ronellenfitsch, 2020, International journal of molecular medicine.

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

M. Weller, W. Wick, J. Steinbach, 2009, Brain : a journal of neurology.

Molecular Determinants of Calcitriol Signaling and Sensitivity in Glioma Stem-like Cells

D. Kögel, K. Lamszus, C. Münch, 2023, bioRxiv.

P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma.

W. Wels, T. Tonn, Congcong Zhang, 2016 .

EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.

J. Fagerberg, P. Wen, A. Idbaih, 2022, Journal of Clinical Oncology.

ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA

E. Seifried, W. Wels, J. Steinbach, 2014 .

Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.

N. Girard, E. Felip, Dong-Wan Kim, 2021 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

K. Langen, E. Hattingen, W. Wels, 2023, Neuro-oncology.